N. Roche (Paris, France), H. Reddel (Glebe, Australia)
The effect of Theophylline in patients with allergic rhinitis: A double-blind, randomised, crossover study
P. Sankaran, C. Brockwell, A. Wilson (Norwich, United Kingdom)
|    |
A prospective study of the effect of carbocysteine lysine salt on COPD exacerbations with or without inhaled steroids
G. Paone, L. Lanata, P. Palermo, M. Bagnasco, S. Toti, F. Saibene, B. Moscatelli, A. Monguzzi, G. Puglisi (Rome, Milan, Italy)
| |
Quantitative computed tomography assessment of airway dimensions by combining tiotropium and indacaterol in patients with COPD
M. Hoshino (Atami, Japan)
| |
Effect of inhaled vilanterol trifenatate/fluticasone furoate on breathing pattern, dyspnea and respiratory muscle function in severe COPD
P. Easton, J. Jagers, M. Ji, K. Olson, M. Johnson, E. Wilde (Calgary, Canada; Uxbridge, United Kingdom)
| |
A double blind placebo controlled study to assess the effect of roflumilast in addition to LABA/LAMA/ICS treatment in COPD patients using novel biomarkers
J. De Backer, W. Vos, C. Van Holsbeke, R. Claes, A. Hufkens, V. Verplancke, L. Bedert, W. De Backer (Kontich, Edegem, Antwerp, Belgium)
| |
Abediterol: Efficacy, safety and tolerability of the novel LABA in patients with persistent asthma
J. Beier, B. Seoane, E. Massana, G. De Miquel, H. Pujol, S. Ruiz (Wiesbaden, Germany; Barcelona, Spain)
| |
Blockade of TSLP pathway alters asthma biomarkers
J. Bigler, M. Boedigheimer, K. Gorski, P. O'Byrne, Y. Wang, G. Gauvreau, L. P. Boulet, D. Cockcroft, M. FitzGerald, B. Davis, C. Dias, L. Smith, E. Bautista, R. Leigh, A. Welcher, J. Parnes (Seattle, Thousand Oaks, United States Of America; Hamilton, Laval, Saskatoon, Vancouver, Calgary, Canada)
| |
A randomized phase 3 study of reslizumab efficacy in relation to blood eosinophil levels in patients with moderate to severe asthma
J. Corren, S. Weinstein, L. Janka, C. O'Brien, J. Zangrilli (Los Angeles, Huntington Beach, Frazer, United States Of America)
| |